目的 观察用骨硬化蛋白抗体拮抗肿瘤细胞骨硬化蛋白(sclerostin)功能对乳腺癌MDA-MB-231 细胞骨转移能力的影响。方法 骨硬化蛋白单链抗体(Sci-Ab)和MDA-MB-231细胞共培养,观察细胞侵袭和迁移能力的改变。24只6～8周龄雌性裸鼠被随机分为两组, 每组12只,每只裸鼠分别以5×106个MDA-MB-231 细胞注射入左侧股骨骨髓腔。对照组注射生理盐水治疗,实验组给予骨硬化蛋白抗体(Sci-Ab)治疗,35 d后行病理检查, 比较两组骨转移发生率和骨肿瘤体积大小。取小鼠股骨,经micro-CT扫描并三维重构,观察各组小鼠骨破坏情况。定量资料的比较采用t检验, 定性资料比较采用Fisher 确切概率检验。结果 MTT实验和划痕实验表明,高浓度的Sci-Ab促进 MDA-MB-231增值和侵袭(P<0.05)。对照组有6 只发生骨转移, 治疗组有9只发生骨转移。治疗组的骨转移发生率虽高于对照组, 但两者差异无统计学意义(P=0.30)。对照组肿瘤平均体积为(0.87±0.244) cm3,治疗组肿瘤平均体积为(0.73±0.118) cm3, 两组间差异无统计学意义(P=0.35)。治疗组的生存率高于对照组,有统计学差异(P<0.05)。Micro-CT分析表明,骨硬化蛋白抗体治疗能够阻止乳腺癌导致的骨损伤并且骨密度高于对照组,两组间差异有统计学意义(P<0.05)。结论 乳腺癌细胞致骨转移能力与骨硬化蛋白表达水平密切相关, 抑制骨硬化蛋白表达可以提高乳腺癌细胞致骨转移的能力,但是能够提高乳腺癌骨转移模型小鼠的生存率,生存率的提高可能与阻止乳腺癌骨转移所介导的骨破坏相关。
Abstract
Objective To investigate the impact of inhibiting the function of sclerostin by antibodies in tumor cells on MDA-MB-231 induced bone metastasis.Methods MDA-MB-231 cells were co-cultured with sclerostin antibody(Sci-Ab). Twenty-four female nude mice aged 6 -8 weeks were divided randomly into two groups (n=12).MDA-MB-231 cells (6×105) were injected into the bone marrow space. The mice were treated with normal saline (NS) and sclerostin antibody (Sci-Ab), respectively. Thirty-five days after the treatment, all the nude mice were subjected to pathological examination to determine bone metastasis.The bone remodelling activities were compared between PBS treatment group and antibody treatment group using micro-CT analysis. Student’s t-test was used for the comparison of quantitative data, and Fisher's exact test was used for the comparison of qualitative data.Results According to MTT assay and Wound Healing, higher Sci-Ab promoted the proliferation and invasion of MDA-MB-231 cells. There were six bone metastasis lesions detected in control group(treated with normal saline) , and nine in experimental group(treated with Sci-Ab) , but there was no statistically significant difference between the two groups(P=0.30) .The bone tumor volume of control group and experimental group was (0.87±0.244) cm3 and (0.73±0.118) cm3, respectively (P=0.35) . The survival of experimental group was significantly longer than that of control group(P<0.05). Micro-CT analysis of the tumor-bearing mice indicated that Sci-Ab was effective in bone protection against breast cancer-induced bone destruction as the bone mineral density (BMD; g/cm2)was significantly increased(P<0.05).Conclusions Bone metastasis from breast cancer is closely correlated with the sclerostin expression level in tumor cells.Inhibiting the expression of sclerostin can promote proliferation and invasion of MDA-MB-231 cells in vitro and improve the survival of mice in vivo.
关键词
乳腺肿瘤 /
骨转移 /
骨硬化蛋白
Key words
breast neoplasms /
bone metastasis /
sclerostin
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Kozlow W, Guise T A. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy[J]. J Mammary Gland Blol, 2005,10(2):169-180.
[2] Early Breast Cancer Trialists’ Collaborative Group. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials[J]. Lancet, 2015,386(10001):1353-1361.
[3] 唐志柳,白 洁,顾丽娜, 等. 2000-2010年我国前列腺癌和乳腺癌流行状况的系统性综述[J]. 中国肿瘤, 2013,22(4):260-265.
[4] Mundy G R. Metastasis to bone: causes, consequences and therapeutic opportunities[J].Nat Rev Cancer, 2002,2(8):584-593.
[5] Mantyh P. Bone cancer pain: causes, consequences, and therapeutic opportunities[J].Pain,2013,154(Suppl 1):S54-562.
[6] Oster G, Lamerato L, Glass A G, et al. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems[J]. Support Care Cancer, 2013,21(12):3279-3286.
[7] 张 帆,杨新华,唐振宁,等. 抑制肿瘤细胞骨保护素表达对乳腺癌细胞致骨转移能力的影响[J]. 中华乳腺病杂志, 2010,4(3):322-327.
[8] Qin W, Zhao W, Li X, et al. Mice with sclerostin gene deletion are resistant to the severe sublesional bone loss induced by spinal cord injury[J]. Osteoporosis Iin, 2016, 27(12): 3627-3636.
[9] van Dinther M, Zhang J, Weidauer S E, et al. Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling[J]. Plos One, 2013, 8(4): e62295.
[10] Li Y, Lu W, King T D, et al. Dkk1 stabilizes Wnt co-receptor LRP6: implication for Wnt ligand-induced LRP6 down-regulation[J]. Plos One, 2010,5(6):e11014.
[11] Khramtsov A I, Khramtsova G F, Tretiakova M, et al. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome[J].Am J Pathol,2010,176(6):2911-2920.
[12] Johnson R W, Merkel A R, Page J M, et al. Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer[J]. Clin Exp Metastas, 2014,31(8):945-959.
[13] Wang X T, He Y C, Zhou S Y, et al. Bone marrow plasma macrophage inflammatory protein protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics[J]. Leukemia Res, 2014,38(5):525-531.
[14] Colucci S, Brunetti G, Oranger A, et al. Myeloma cells suppress osteoblasts through sclerostin secretion[J]. Blood Cancer J, 2011,1(6):e27.
[15] Tang P, Yao Q, Zhang W, et al. A study of femoral neck fracture repair using a recombinant human bone morphogenetic protein-2 directional release system[J]. Tissue Eng Part A, 2009,15(12):3971-3978.
[16] 姚 琦,张立才,倪 杰,等. 抗Sclerostin单链抗体基因的构建、表达及活性分析[J]. 武警医学, 2013,24(12):1047-1052.
[17] 方琼英,吴 琼,张秀玲,等. 乳腺癌的流行现状分析[J]. 中国社会医学杂志, 2012,29(5):333-335.
[18] Brunetti G, Oranger A, Mori G, et al. Sclerostin is overexpressed by plasma cells from multiple myeloma patients[J]. Ann Ny Acad Sci, 2011,1237(1):19-23.
[19] Li X, Xu Y, Chen Y, et al. SOX2 promotes tumor metastasis by stimulating epithelial-to-mesenchymal transition via regulation of WNT/beta-catenin signal network[J]. Cancer Lett, 2013, 336(2): 379-389.
[20] Yamada N, Noguchi S, Mori T, et al. Tumor-suppressive microRNA-145 targets catenin delta-1 to regulate Wnt/beta-catenin signaling in human colon cancer cells[J]. Cancer Lett, 2013,335(2):332-342.
[21] Schouten C, Meijer G J, van den Beucken J J, et al. The quantitative assessment of peri-implant bone responses using histomorphometry and micro-computed tomography[J]. Biomaterials, 2009,30(27):4539-4549.
[22] Ji W, Yang F, Ma J, et al. Incorporation of stromal cell-derived factor-1alpha in PCL/gelatin electrospun membranes for guided bone regeneration[J]. Blomaterials, 2013,34(3):735-745.
[22] Hambli R. Micro-CT finite element model and experimental validation of trabecular bone damage and fracture[J]. Bone, 2013,56(2):363-374.
[24] Eda H, Santo L, Wein MN, et al. Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease[J]. J Bone Miner Ras, 2016,31(6):1225-1234.
基金
北京市科学技术委员会基金(Z151100003915094),中国医师协会(编号:2015-A35)。
PDF(3568 KB)
